Skip to content
HowShorted

Immunome, Inc. short interest in 2025

In 2025, Immunome, Inc.'s disclosed short interest ran from 16.89% of shares outstanding on 15 Jan 2025 to 19.12% on 31 Dec 2025, a change of +2.23 percentage points. The year's high was 19.12% on 31 Dec 2025 and its low 10.95% on 14 Mar 2025, averaging 15.68% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.94 days on 29 Aug 2025. Full history: Immunome, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Immunome, Inc. in 2025

2025 in figures

Start of year
16.89% (15 Jan 2025)
End of year
19.12% (31 Dec 2025)
Change
+2.23 pp
High
19.12% (31 Dec 2025)
Low
10.95% (14 Mar 2025)
Average
15.68%
Highest days to cover
21.94 (29 Aug 2025)
SEC filings marked
9

Every report in 2025

Immunome, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202516.89%16.98
31 Jan 202514.53%7.10results (8-K)
14 Feb 202514.98%8.82
28 Feb 202514.90%13.01
14 Mar 202510.95%14.23
31 Mar 202512.80%6.1510-K filed, results (8-K)
15 Apr 202514.36%9.97
30 Apr 202515.69%12.60
15 May 202514.63%12.4910-Q filed, results (8-K)
30 May 202515.23%15.08
13 Jun 202514.40%15.54
30 Jun 202514.47%10.29
15 Jul 202516.33%14.02
31 Jul 202516.35%17.03
15 Aug 202515.81%20.7110-Q filed, results (8-K)
29 Aug 202515.58%21.94
15 Sep 202517.20%10.12
30 Sep 202517.77%7.40
15 Oct 202517.50%10.12
31 Oct 202517.34%14.64
14 Nov 202515.62%8.4010-Q filed, results (8-K)
28 Nov 202516.65%14.42
15 Dec 202517.31%7.35
31 Dec 202519.12%5.14

See also: Immunome, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.